Ultragenyx Pharmaceutical Inc.
RARE
$23.40
$0.652.86%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Total Cash And Short-Term Investments | 425.25M | 487.59M | 494.44M | 610.03M | 607.51M |
| Total Receivables | 116.34M | 127.36M | 102.84M | 123.60M | 95.10M |
| Inventory | 52.20M | 46.50M | 46.03M | 45.01M | 43.33M |
| Prepaid Expenses | 39.59M | 49.31M | 47.37M | 31.68M | -- |
| Finance Division Loans and Leases Current | -- | -- | -- | -- | -- |
| Total Finance Division Other Current Assets | -- | -- | -- | -- | -- |
| Other Current Assets | 9.83M | 9.04M | 8.48M | 6.81M | 53.67M |
| Total Current Assets | 643.21M | 719.79M | 699.16M | 817.12M | 799.61M |
|
|
|||||
| Total Current Assets | 643.21M | 719.79M | 699.16M | 817.12M | 799.61M |
| Net Property, Plant & Equipment | 249.96M | 255.76M | 260.91M | 291.43M | 272.45M |
| Long-term Investments | 44.41M | 44.41M | 44.41M | 44.41M | 44.41M |
| Goodwill | 44.41M | 44.41M | 44.41M | 44.41M | 44.41M |
| Total Other Intangibles | 172.94M | 174.73M | 176.52M | 178.31M | 164.94M |
| Finance Div Loans & Leases LT | -- | -- | -- | -- | -- |
| Total Finance Div Other LT Assets | -- | -- | -- | -- | -- |
| Total Other Assets | 57.86M | 60.12M | 62.37M | 37.18M | 53.87M |
| Total Assets | 1.19B | 1.31B | 1.31B | 1.50B | 1.54B |
|
|
|||||
| Total Accounts Payable | 40.57M | 34.24M | 47.45M | 38.76M | 35.99M |
| Total Accrued Expenses | 220.53M | 180.79M | 173.01M | 240.97M | 185.03M |
| Short-term Debt | -- | -- | -- | -- | -- |
| Current Portion of Long-Term Debt/Capital Leases | -- | -- | -- | -- | -- |
| Finance Division Debt Current | 77.69M | 75.63M | 67.86M | 60.14M | 59.16M |
| Total Finance Division Other Current Liabilities | 1.24M | 2.58M | 3.35M | 4.28M | 4.84M |
| Total Other Current Liabilities | 1.24M | 2.58M | 3.35M | 4.28M | 4.84M |
| Total Current Liabilities | 340.02M | 293.24M | 291.67M | 344.15M | 285.01M |
|
|
|||||
| Total Current Liabilities | 340.02M | 293.24M | 291.67M | 344.15M | 285.01M |
| Long-Term Debt | 763.74M | 782.75M | 794.05M | 819.82M | 829.69M |
| Short-term Debt | -- | -- | -- | -- | -- |
| Capital Leases | 21.69M | 24.53M | 27.79M | 30.04M | 23.66M |
| Finance Division Debt Non Current | -- | -- | -- | -- | -- |
| Total Finance Division Other Non Current Liabilities | -- | -- | -- | -- | -- |
| Total Other Liabilities | 48.84M | 47.46M | 47.18M | 47.14M | 46.19M |
| Total Liabilities | 1.17B | 1.15B | 1.16B | 1.24B | 1.18B |
|
|
|||||
| Common Stock & APIC | 4.41B | 4.37B | 4.25B | 4.21B | 4.17B |
| Retained Earnings | -4.40B | -4.22B | -4.11B | -3.96B | -3.82B |
| Treasury Stock & Other | 820.00K | -268.00K | -341.00K | -643.00K | 896.00K |
| Total Common Equity | 9.16M | 151.29M | 144.25M | 255.30M | 346.83M |
|
|
|||||
| Preferred Stock Redeemable | -- | -- | -- | -- | -- |
| Preferred Stock Non Redeemable | -- | -- | -- | -- | -- |
| Preferred Stock Convertible | -- | -- | -- | -- | -- |
| Preferred Stock, Others | -- | -- | -- | -- | -- |
| Total Preferred Equity | -- | -- | -- | -- | -- |
|
|
|||||
| Total Common Equity | 9.16M | 151.29M | 144.25M | 255.30M | 346.83M |
| Total Preferred Equity | -- | -- | -- | -- | -- |
| Total Minority Interest | 7.00M | 7.00M | 7.00M | 7.00M | 7.00M |
| Total Equity | 16.16M | 158.29M | 151.25M | 262.30M | 353.83M |
|
|
|||||